您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Imiquimod
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Imiquimod
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Imiquimod图片
CAS NO:99011-02-6
规格:≥98%
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议
1g电议
2g电议
5g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 240.3
Formula C14H16N4
CAS No. 99011-02-6
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 2.4 mg/mL
Water: NA
Ethanol: NA
Chemical Name1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
SynonymsS26308; R 837; TMX-101; S 26308; R837; TMX 101; S-26308; R837; TMX101; Brand names: Aldara; Zyclara; Vyloma; Beselna.
SMILES CodeNC1=NC2=CC=CC=C2C3=C1N=CN3CC(C)C
实验参考方法
In Vitro

In vitro activity: Imiquimod is an immune response modifier that acts as an agonist of the TLR7 (toll-like receptor 7). Imiquimod is a prescription medication that is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis. Scientists at 3M's pharmaceuticals division discovered the drug and 3M obtained the first FDA approval in 1997 under the brand name of Aldara. As of 2015, imiquimod is generic and is available worldwide under many brands. Imiquimod signals to the innate arm of the immune system through the TLR7, commonly involved in pathogen recognition. Cells activated by imiquimod via TLR-7 secrete cytokines such as interferon-α (INF-α), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Imiquimod has been studied in combination with pembrolizumab for treating stage IIIB-IV melanoma.

In VivoImiquimod stimulates the innate immune response by increasing NK cell activity, activating macrophages to secrete cytokines and nitric oxide, and inducing proliferation and differentiation of B lymphocytes in animal models. Imiquimod stimulates the innate immune response through induction, synthesis, and release of cytokines, including interferon-a (IFN-α), interleukin (IL)-6, and tumour necrosis factor (TNF)-α
Animal modelTissue ELISA revealed that imiquimod specifically reduced IL-1β and IL-6 secretion in the treated mouse paws (Panels F-G), whereas neutrophil infiltration (visualized by MPO quantification, Panel H) and TNF-α production (panel I) remained unaffected. RTqPCR and western blot analysis further documented the negative effect of imiquimod on the transcription of the Il-1β and Il-6 genes (Panels J-K) and IL-1β pro-form expression (Panel L).
Formulation & Dosage
References Actas Dermosifiliogr. 2018 May 23. pii: S0001-7310(18)30177-7; Br J Dermatol. 2003 Nov;149 Suppl 66:5-8.; Theranostics. 2020; 10(5): 2158–2171.